跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

SML2196

Sigma-Aldrich

Zotarolimus

≥95% (HPLC)

别名:

(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin, ABT-578

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C52H79N5O12
CAS号:
221877-54-9
分子量:
966.21
MDL號碼:
MFCD09752954
分類程式碼代碼:
51111800
NACRES:
NA.77

化驗

≥95% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

C[C@H](CC[C@@H](C[C@H](OC)/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@H](OC)[C@@H](/C(C)=C/[C@@H](C)C1=O)O)=O)C)C)O2)[C@]2(O)C(C(N3CCCC[C@H]3C(O[C@H]([C@H](C)C[C@@H]4CC[C@H](N5N=NN=C5)[C@H](OC)C4)C1)=O)=O)=O

InChI

1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1

InChI 密鑰

CGTADGCBEXYWNE-JUKNQOCSSA-N

生化／生理作用

Zotarolimus (ABT-578) is a semi-synthetic rapamycin analog with immunosuppressant and anti-proliferative activity. It binds to the FKBP12 binding protein, which subsequently binds to the mammalian target of rapamycin (mTOR) causing cell cycle arrest in the G1 phase. Zotarolimus was designed to be used for delivery from drug-eluting coronary stents to prevent restenosis.
Zotarolimus is a second generation Drug Eluting Stent (DES).

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Fabrizio D'Ascenzo et al.
European heart journal, 38(42), 3160-3172 (2017-10-12)
The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Randomized controlled trials
Yuji Nishimoto et al.
Journal of cardiology, 70(3), 297-302 (2016-12-31)
First-generation drug-eluting stents (DES) have reduced short-term stent failure as compared to bare-metal stents due to the inhibition of neointima hyperplasia, but instead increased the risk of very-late stent failure. Although better outcomes have been reported for second-generation DES than
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates
Valgimigli M, et al.
Journal of the American College of Cardiology, 65(8), 805-815 (2015)
Keiichiro Miura et al.
Cardiovascular revascularization medicine : including molecular interventions, 16(6), 344-347 (2015-08-09)
Late and very late stent thrombosis after drug-eluting stent implantation is a major concern. The present study evaluated difference in the effects of sirolimus, paclitaxel and zotarolimus on endothelial cells. Mouse endothelial cells were seeded in a 6-well plate. Cells

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门